Methods and Compostions for the Treatment of Immune Disorders and Regulation of Cytokine and Growth Factor Signaling
Categories: Pharmaceuticals: Central Nervous System Disorders, Immune and Inflammatory Disorders Biotechnology: Assays, Diagnostics, Model Systems
Background: Mgat5 is an enzyme that glycosylates T-cell receptors to modulate T-cell activation and autoimmune response. Mgat5 Null PL/J Mice were developed as part of a study performed by scientists at Mount Sinai Hospital and the University of California, Irvine to establish an understanding of the role of Mgat5 modified glycans in the regulation of autoimmunity. Technology: Mgat5 Null PL/J Mice present an improved model for studies of multiple sclerosis and treatments thereof. Mice lacking Mgat5 have an experimentally demonstrated inability to prevent autoimmune response to myelin thus displaying CNS pathology similar to chronic MS plaques.
The results of the study formed the basis for a multiple sclerosis diagnostic that can detect deficiencies in Mgat5 modified glycans. A small molecule drug that compensates for these deficiencies has been proven effective in the Mgat5 Null PL/J animal model.
Application: A method for diagnosing multiple sclerosis (MS) by detecting the presence of various molecules involved in the T-cell activation pathway, and compounds to treat and prevent progression of the disease upon assessment of the results. The technology also encompasses an effective animal model of MS and systems for screening MS related therapeutic compounds.
The end users of the therapeutic will be MS patients.
Type of Offer:
« More Biotech Patents« More Pharmaceutical Patents